Gritstone bio Inc.

09/17/2021 | Press release | Distributed by Public on 09/17/2021 05:04

Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial